advanced search
Aptar Pharma

Pulmonary & Nasal Delivery102

Issue No #102 Nov 2019  November 8th, 2019


Download PDF


Inside the magazine

DRY POWDER INHALERS: TOWARDS EFFECTIVE, AFFORDABLE, SUSTAINABLE RESPIRATORY HEALTHCARE
PULMONARY
Dr João Ventura Fernandes
Hovione Technology Ltd
DRY POWDER INHALERS: TOWARDS EFFECTIVE, AFFORDABLE, SUSTAINABLE RESPIRATORY HEALTHCARE
João Ventura Fernandes and Peter Villax look at the trends shaping the development of dry powder inhalers, highlighting the need for a shift in industrial strategy towards effective, globally affordable, sustainable devices.
PATIENT SAFETY: KEY DRIVER TO PRESERVATIVE-FREE NASAL SPRAY DEVELOPMENT
NASAL
Benoit Guillard
Nemera
PATIENT SAFETY: KEY DRIVER TO PRESERVATIVE-FREE NASAL SPRAY DEVELOPMENT
Benoît Guillard, Pascale Farjas  and Audrey Chandra look at the effects of preservatives in nasal sprays, and the challenges and advantages of delivering preservative-free nasal spray drugs.
MANUFACTURING DPIS: CASE STUDY OF IMA ADAPTA<sup>®</sup> WITH BOEHRINGER INGELHEIM SPIRIVA<sup>®</sup>
INDUSTRIALISATION
Rainer Bauer
IMA Group
MANUFACTURING DPIS: CASE STUDY OF IMA ADAPTA® WITH BOEHRINGER INGELHEIM SPIRIVA®
Pietro Piera  and Rainer Bauer investigate the optimal process parameters for low-dose dry powder inhalers achieved by dosator technology, presenting a case study in which IMA’s capsule filler, Adapta®, is used to fill Boehringer Ingelheim’s Spiriva® (tiotropium) dry powder inhaler.
ENHANCING INHALATION THERAPY BY REINTRODUCING ANTIBIOTICS USING MESH TECHNOLOGY
PULMONARY
Edgar Hernan Cuevas Brun
HCmed Innovations
ENHANCING INHALATION THERAPY BY REINTRODUCING ANTIBIOTICS USING MESH TECHNOLOGY
Edgar Hernan Cuevas Brun looks at how the administration of some old antibiotics could be a valuable response to fight infections.
REDUCING VASCULAR MORTALITY IN PATIENTS WITH SUSPECTED ACUTE MI
EARLY INSIGHT
Mark Stansfield
Otitopic
REDUCING VASCULAR MORTALITY IN PATIENTS WITH SUSPECTED ACUTE MI
Mark Stansfield and Kambiz Yadidi discuss initial results of their pilot Phase I clinical study of dry powder inhalation formulation of aspirin for the treatment of acute myocardial infarction.
A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE
RESPIRATORY
Dr Jag Shur
Nanopharm
A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE
Jag Shur explores the challenges companies face in bringing generic respiratory and nasal therapies to market – and how some organisations have proactively addressed the challenge and developed services to integrate the device and the formulation, introducing the Aptar Pharma Services offering.
HOW A DIGITAL APPROACH CAN UNPICK CLINICAL TRIAL CHALLENGES AND IMPROVE OUTCOMES
EXPERT VIEW
Dr Matt Ash
HOW A DIGITAL APPROACH CAN UNPICK CLINICAL TRIAL CHALLENGES AND IMPROVE OUTCOMES
Matt Ash, Tom Lawrie-Fussey and Bastiaan De Leeuw look at the role digital technology can play in the development of drug-device combination products.
IN VITRO BIOEQUIVALENCE – WHERE ARE WE NOW?
PULMONARY
Mark Parry
Intertek Melbourn
IN VITRO BIOEQUIVALENCE – WHERE ARE WE NOW?
With a focus on bioequivalence testing in generic inhalables development, Mark Parry highlights shortcomings of aerodynamic particle size distribution and delivered dose testing, and introduces newer testing techniques.
HOW TO GAIN A FULL UNDERSTANDING OF POWDER FLOW PROPERTIES, AND THE BENEFITS OF DOING SO
RESPIRATORY
Dr Geoffroy Lumay
Granutools
HOW TO GAIN A FULL UNDERSTANDING OF POWDER FLOW PROPERTIES, AND THE BENEFITS OF DOING SO
Geoffroy Lumay, Naveen Mani Tripathi and Filip Francqui show how the association of three recently developed flow measurement techniques can be used to gain valuable insights into powder properties and characteristics.
WHEN EVERY SECOND COUNTS…
NASAL
Dr Todd Pizitz
CounterAct
WHEN EVERY SECOND COUNTS…
Todd Pizitz and Donald Mealing look at efforts to reduce the number of opioid-related deaths in the United States, and introduce a nasal device that delivers naloxone.
REGULATORY AFFAIRS: THE UNDERESTIMATED ROLE OF PRIMARY PACKAGING
RESPIRATORY
Dr Antje Caelers
Sanner
REGULATORY AFFAIRS: THE UNDERESTIMATED ROLE OF PRIMARY PACKAGING
Antje Caelers explains how increasingly complex products and production chains, restrictive industry standards and differing regulations mean that regulatory affairs are becoming more important than ever.
Top

W3 Total Cache is currently running in Pro version Development mode.